Reduction in Osteoarthritis Risk After Treatment With Ticagrelor Compared to Clopidogrel: A Propensity Score–Matching Analysis
- 3 October 2020
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 72 (11) , 1829-1835
Abstract
Objective: Osteoarthritis (OA) is a common cause of joint pain and disability, and effective treatments are lacking. Extracellular adenosine has antiinflammatory effects and can prevent and treat OA in animal models. Ticagrelor and clopidogrel are both used in patients with coronary artery disease, but only ticagrelor increases extracellular adenosine levels. This study was undertaken to determine whether treatment with ticagrelor was associated with a lower risk of OA.Methods: We conducted a 1:2 propensity score–matching analysis using data from 2011–2017 in the Optum Clinformatics Data Mart. Patients who had received either ticagrelor or clopidogrel for ≥90 days were included in our study, and patients with a prior diagnosis of OA or inflammatory arthritis were excluded. OA was identified using International Classification of Diseases codes. The primary outcome was the time to diagnosis of OA after treatment with ticagrelor versus clopidogrel.Results: Our propensity score–matched cohort consisted of 7,007 ticagrelor‐treated patients and 14,014 clopidogrel‐treated patients, with a median number of days receiving treatment of 287 and 284, respectively. For both groups, the mean age was 64 years, and 73% of the patients were male. Multivariate Cox regression analysis estimated a hazard ratio for developing OA of 0.71 (95% confidence interval 0.64–0.79) (P < 0.001) after treatment with ticagrelor compared to clopidogrel.Conclusion: Treatment with ticagrelor was associated with a 29% lower risk of developing OA compared to treatment with clopidogrel over 5 years of follow‐up. We hypothesize that the reduction in OA seen in patients who received ticagrelor may in part be due to increased extracellular adenosine levels.Keywords
Funding Information
- National Center for Advancing Translational Sciences (KL2TR003143)
This publication has 24 references indexed in Scilit:
- Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkersNature Reviews Rheumatology, 2016
- Ticagrelor regulates osteoblast and osteoclast function and promotes bone formation in vivo via an adenosine‐dependent mechanismThe FASEB Journal, 2016
- OsteoarthritisThe Lancet, 2015
- Adenosine-Mediated Effects of TicagrelorJACC, 2014
- Ticagrelor Increases Adenosine Plasma Concentration in Patients With an Acute Coronary SyndromeJACC, 2014
- The use of propensity score methods with survival or time‐to‐event outcomes: reporting measures of effect similar to those used in randomized experimentsStatistics in Medicine, 2013
- Osteoarthritis: an update with relevance for clinical practiceThe Lancet, 2011
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studiesPharmaceutical Statistics, 2011
- Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 CountriesAmerican Journal of Epidemiology, 2011
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IIArthritis & Rheumatism, 2007